Axial - Cipher #5 (gene therapy)
Finding the other half
Analysis of public clinical and business development data in life sciences.
Gene therapies have been on a rollercoaster over the last few decades:
With Spark Therapeutics getting the first AAV approval and Bluebird Bio, uniQure, AveXis doing incredible work. The average gene therapy deal value peaked around $200M with the number of partnerships seeing a marked rise in early 2010:
With a focus on research and licensing agreements:
Focused on discovery and foundation work:
With deals having no geographic preference: